Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1993 Sep;36(3):263–265. doi: 10.1111/j.1365-2125.1993.tb04227.x

Steady state serum concentrations of pravastatin and digoxin when given in combination.

J Triscari 1, B N Swanson 1, D A Willard 1, A I Cohen 1, A Devault 1, H Y Pan 1
PMCID: PMC1364648  PMID: 9114914

Abstract

Pravastatin is an HMG CoA reductase inhibitor used in the treatment of hypercholesterolaemia. The steady state pharmacokinetics of pravastatin (20 mg) and digoxin (0.2 mg) were evaluated in 18 healthy male subjects following the administration of each drug alone or in combination for 9 days. Serum and urine were collected for up to 48 h after the ninth dose in this open, randomized 3-way crossover study. Digoxin concentrations were measured by radioimmunoassay, and pravastatin and its metabolites. SQ 31,906 and SQ 31,945 were measured by GC-MS. Digoxin and pravastatin pharmacokinetics were unchanged following combined administration. Combination therapy with pravastatin and digoxin is unlikely to expose patients to additional risk compared with pravastatin alone.

Full text

PDF
263

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Everett D. W., Chando T. J., Didonato G. C., Singhvi S. M., Pan H. Y., Weinstein S. H. Biotransformation of pravastatin sodium in humans. Drug Metab Dispos. 1991 Jul-Aug;19(4):740–748. [PubMed] [Google Scholar]
  2. Funke P. T., Ivashkiv E., Arnold M. E., Cohen A. I. Determination of pravastatin sodium and its major metabolites in human serum/plasma by capillary gas chromatography/negative ion chemical ionization mass spectrometry. Biomed Environ Mass Spectrom. 1989 Oct;18(10):904–909. doi: 10.1002/bms.1200181010. [DOI] [PubMed] [Google Scholar]
  3. Halstenson C. E., Triscari J., DeVault A., Shapiro B., Keane W., Pan H. Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment. J Clin Pharmacol. 1992 Feb;32(2):124–132. doi: 10.1002/j.1552-4604.1992.tb03816.x. [DOI] [PubMed] [Google Scholar]
  4. Hunninghake D. B., Knopp R. H., Schonfeld G., Goldberg A. C., Brown W. V., Schaefer E. J., Margolis S., Dobs A. S., Mellies M. J., Insull W., Jr Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study. Atherosclerosis. 1990 Nov;85(1):81–89. doi: 10.1016/0021-9150(90)90185-l. [DOI] [PubMed] [Google Scholar]
  5. Pan H. Y., DeVault A. R., Swites B. J., Whigan D., Ivashkiv E., Willard D. A., Brescia D. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther. 1990 Aug;48(2):201–207. doi: 10.1038/clpt.1990.136. [DOI] [PubMed] [Google Scholar]
  6. Pan H. Y., DeVault A. R., Wang-Iverson D., Ivashkiv E., Swanson B. N., Sugerman A. A. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol. 1990 Dec;30(12):1128–1135. doi: 10.1002/j.1552-4604.1990.tb01856.x. [DOI] [PubMed] [Google Scholar]
  7. Pan H. Y., Triscari J., DeVault A. R., Smith S. A., Wang-Iverson D., Swanson B. N., Willard D. A. Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin. Br J Clin Pharmacol. 1991 Jun;31(6):665–670. doi: 10.1111/j.1365-2125.1991.tb05590.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Singhvi S. M., Pan H. Y., Morrison R. A., Willard D. A. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol. 1990 Feb;29(2):239–243. doi: 10.1111/j.1365-2125.1990.tb03626.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES